Cargando…

Computed CD4 percentage as a low-cost method for determining pediatric antiretroviral treatment eligibility

BACKGROUND: The performance of the WHO recommendations for pediatric antiretroviral treatment (ART) in resource poor settings is insufficiently documented in routine care. METHODS: We compared clinical and immunological criteria in 366 children aged 0 to 12 years in Kinshasa and evaluated a simple c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Callens, Steven FJ, Kitetele, Faustin, Lusiama, Jean, Shabani, Nicole, Edidi, Samuel, Colebunders, Robert, Behets, Frieda, Van Rie, Annelies
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2292192/ https://www.ncbi.nlm.nih.gov/pubmed/18325119 http://dx.doi.org/10.1186/1471-2334-8-31

Ejemplares similares

Pulmonary cystic disease in HIV positive individuals in the Democratic Republic of Congo: three case reports
por: Callens, Steven FJ, et al.
Publicado: (2007)

The Effect of Highly Active Antiretroviral Therapy on the Survival of HIV-Infected Children in a Resource-Deprived Setting: A Cohort Study
por: Edmonds, Andrew, et al.
Publicado: (2011)

Training health care workers to promote HIV services for patients with tuberculosis in the Democratic Republic of Congo
por: Driessche, Koen Vanden, et al.
Publicado: (2009)

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs
por: Haslam, Alyson, et al.
Publicado: (2020)

Derivation of parameters used in Spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy
por: Mahy, Mary, et al.
Publicado: (2010)

Lessons Learned from the Impact of HIV Status Disclosure to Children after First-Line Antiretroviral Treatment Failure in Kinshasa, DR Congo
por: Kitetele, Faustin Nd., et al.
Publicado: (2022)

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
por: Haslam, Alyson, et al.
Publicado: (2019)

CD4 Enumeration Technologies: A Systematic Review of Test Performance for Determining Eligibility for Antiretroviral Therapy
por: Peeling, Rosanna W., et al.
Publicado: (2015)

Relationship Between Time to Initiation of Antiretroviral Therapy and Treatment Outcomes: A Cohort Analysis of ART Eligible Adolescents in Zimbabwe
por: Vogt, Florian, et al.
Publicado: (2017)

Impact of WHO 2010 Guidelines on Antiretroviral Therapy Initiation among Patients with HIV-Associated Tuberculosis in Clinics with and without Onsite HIV Services in the Democratic Republic of Congo
por: Yotebieng, Marcel, et al.
Publicado: (2016)

Continuous quality improvement interventions to improve long-term outcomes of antiretroviral therapy in women who initiated therapy during pregnancy or breastfeeding in the Democratic Republic of Congo: design of an open-label, parallel, group randomized trial
por: Yotebieng, Marcel, et al.
Publicado: (2017)

Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib
por: de Almeida Carvalho, Lelia Maria, et al.
Publicado: (2019)

Evaluation of Portable Point-of-Care CD4 Counter with High Sensitivity for Detecting Patients Eligible for Antiretroviral Therapy
por: Manabe, Yukari C., et al.
Publicado: (2012)

Conditional Cash Transfers to Increase Retention in PMTCT Care, Antiretroviral Adherence, and Postpartum Virological Suppression: A Randomized Controlled Trial
por: Yotebieng, Marcel, et al.
Publicado: (2016)

Hepatitis B infection among pregnant and post-partum women living with HIV and on antiretroviral therapy in Kinshasa, DR Congo: A cross-sectional study
por: Mpody, Christian, et al.
Publicado: (2019)

Pediatric urology: Development, eligibility, practice
por: Bajpai, M.
Publicado: (2009)

Higher CD27(+)CD8(+) T Cells Percentages during Suppressive Antiretroviral Therapy Predict Greater Subsequent CD4(+) T Cell Recovery in Treated HIV Infection
por: Seu, Lillian, et al.
Publicado: (2013)

Maximum Percentage Contribution to the Cost of the Basic Programme
Publicado: (1971)

Maximum Percentage Contribution to the Cost of the Basic Programme
Publicado: (1971)

CD4 Variability in Malawi: Implications for Use of a CD4 Threshold of 500 Cells/mm(3) Versus Universal Eligibility for Antiretroviral Therapy
por: Schooley, Alan L., et al.
Publicado: (2016)

Conducting Unlinked Anonymous HIV Surveillance in Developing Countries: Ethical, Epidemiological, and Public Health Concerns
por: Rennie, Stuart, et al.
Publicado: (2009)

Simulated clients reveal factors that may limit contraceptive use in Kisumu, Kenya
por: Tumlinson, Katherine, et al.
Publicado: (2013)

Infant feeding practices and determinants of poor breastfeeding behavior in Kinshasa, Democratic Republic of Congo: a descriptive study
por: Yotebieng, Marcel, et al.
Publicado: (2013)

Screening HIV-infected adults in Malawi for anaemia: impact on eligibility for antiretroviral therapy
por: Page, I D, et al.
Publicado: (2013)

Reduction in Early Mortality on Antiretroviral Therapy for Adults in Rural South Africa Since Change in CD4(+) Cell Count Eligibility Criteria
por: Lessells, Richard J., et al.
Publicado: (2014)

Changing Antiretroviral Eligibility Criteria: Impact on the Number and Proportion of Adults Requiring Treatment in Swaziland
por: Bock, Naomi N., et al.
Publicado: (2016)

Clinician Perspectives on Delaying Initiation of Antiretroviral Therapy for Clinically Eligible HIV-Infected Patients
por: Beer, Linda, et al.
Publicado: (2015)

Risk factors for mortality among malnourished HIV-infected adults eligible for antiretroviral therapy
por: Woodd, Susannah L, et al.
Publicado: (2016)

Decreased percentage of CD4(+)Foxp3(+)TGF-β(+) and increased percentage of CD4(+)IL-17(+) cells in bronchoalveolar lavage of asthmatics
por: Barczyk, Adam, et al.
Publicado: (2014)

Percentage and function of CD4(+)CD25(+) regulatory T cells in patients with hyperthyroidism
por: Jiang, Ting-Jun, et al.
Publicado: (2018)

Colon Cancer Treatment Costs for Medicare and Dually Eligible Beneficiaries
por: Luo, Zhehui, et al.
Publicado: (2009)

Cancer Treatment for Dual Eligibles: What Are the Costs and Who Pays?
por: Haber, Susan G., et al.
Publicado: (2013)

Current Eligibility Requirements for CGM Coverage Are Harmful, Costly, and Unjustified
por: Anderson, John E., et al.
Publicado: (2020)

The clock is ticking: the rate and timeliness of antiretroviral therapy initiation from the time of treatment eligibility in Kenya
por: Odeny, Thomas A, et al.
Publicado: (2015)

Increased Regulatory T-Cell Percentage Contributes to Poor CD4(+) Lymphocytes Recovery: A 2-Year Prospective Study After Introduction of Antiretroviral Therapy
por: Saison, Julien, et al.
Publicado: (2015)

Time to eligibility for antiretroviral therapy in adults with CD4 cell count > 500 cells/μL in rural KwaZulu-Natal, South Africa
por: McGrath, N, et al.
Publicado: (2015)

The role of disclosure in relation to assent to participate in HIV-related research among HIV-infected youth: a formative study
por: Corneli, Amy, et al.
Publicado: (2009)

Postpartum depressive symptoms following implementation of the 10 steps to successful breastfeeding program in Kinshasa, Democratic Republic of Congo: A cohort study
por: Agler, Robert A., et al.
Publicado: (2021)

Pediatric Secondary Transfer Percentages: A Retrospective Observational Study
por: Leroux, Yves, et al.
Publicado: (2020)

What Is the Optimal First Line Antiretroviral Therapy in Resource-Limited Settings?
por: Kenyon, Chris, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_o03fqg9e2q61imamir2nprrm39